"Half of all heart attacks are a complete surprise."

That line isn't mine. It's from John Farquhar, CEO of HeartFlow (HTFL), at a Morgan Stanley conference last week. Let me repeat it so it sinks in: half the people who have heart attacks had already been through the healthcare system and nobody diagnosed them properly.

Damn, if that doesn't scare you, nothing will.

What HeartFlow Actually Does (in Plain English)

Forget the jargon and the medical mumbo-jumbo for a second. HeartFlow is, at its core, a tech company that uses artificial intelligence to diagnose coronary artery disease. The kind that clogs your arteries and, one fine day, sends you to the other side without so much as a heads-up.

Heart disease is the number one killer on the planet. It kills more than all types of cancer combined. Every 40 seconds, someone in the U.S. has a heart attack. And the healthcare system, with all its pomp, all its technology, all its billion-dollar bureaucracy, gets the diagnosis wrong half the time.

It's like having the best alarm system in the neighborhood — and it doesn't go off when the burglar walks through the front door.

HeartFlow's pitch is simple in concept and complex in execution: use AI to create a new standard of care. Take imaging exams that already exist and extract information from them that the human eye — no matter how well-trained — can't consistently catch.

The Morgan Stanley Conference: The Stage and the Players

Farquhar presented at the Morgan Stanley Technology, Media & Telecom Conference 2026. Notice the detail: technology conference, not healthcare. That's no accident. HeartFlow wants to be seen as a tech company, not just another boring healthtech burning cash and promising paradise.

And look, the CEO dropped the magic phrase every growth investor wants to hear: "we're in the early innings."

If you follow the American market, you know that expression is a classic. It means: "We've barely started, the market is massive, we're just scratching the surface." It's the kind of line that makes sell-side analysts drool and build DCF models with generous terminal rates.

But let's pump the brakes.

Where Healthy Skepticism Lives

I'm all for AI applied to medicine. I'm all for technology that saves lives. Who isn't? But the medical thesis is one thing, the investment thesis is another. And this is where Nassim Taleb would walk into the room and ask: "Who has skin in the game?"

HeartFlow is a public company that needs to deliver results. The cardiac diagnostics market is enormous — nobody disputes that. But "enormous market" is the favorite excuse of every company that hasn't yet proven it can scale with margin.

Questions you should be asking before putting a single penny into this story:

1) What's the real barrier to entry? If AI is the differentiator, what's stopping a Google Health, a Microsoft Nuance, a Philips, or a Siemens Healthineers from building something similar with hospital access that HeartFlow can only dream of?

2) Reimbursement. In the world of American healthcare, it doesn't matter how good your technology is if insurance won't pay for it. The reimbursement policies of Medicare and private insurers are the real judge here, not the scientific paper.

3) Clinical adoption is slow. Doctors are, by nature and training, conservative. Convincing a 55-year-old cardiologist to trust an AI over his own clinical judgment is like convincing your uncle to trade in his stick shift for an electric car. It happens, but it takes time.

4) The company is in those so-called "early innings" — translation: it's probably burning cash like firewood at a Fourth of July bonfire. How long will the market stay patient?

A Movie I've Seen Before

This reminds me of Theranos. Hold on — I'm not comparing ethics or fraud — HeartFlow is a legitimate company with FDA clearance. But the narrative script is similar: "Revolutionary technology + massive health problem + charismatic founder = blank check."

The difference between a brilliant investment and a trap usually isn't in the story. It's in the numbers. In the boring details nobody discusses at a glamorous Morgan Stanley conference.

So before you hop on the hype train, do your homework. Read the 10-K. Look at the cash burn. Understand the regulatory pipeline. And most importantly: ask yourself if you understand this business well enough to stomach a 40% drop without panic-selling.

Because if the answer is no, you're not an investor. You're a fan.

And fans, in the market, are just another word for victims.